Clinical trial · no report yet · Phase 2
PASS-01
Pancreatic Adenocarcinoma Signature Stratification for Treatment
- NCT04469556 ↗
- Completed
- University Health Network, Toronto
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 23 | |
| Podcasts | 3 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- Pancreatic Adenocarcinoma Signature Stratification for Treatment
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Pancreatic Cancer Metastatic; Pancreatic Ductal Adenocarcinoma; Advanced Pancreatic Cancer
- Interventions
- Folfirinox; Gemcitabine/nab-paclitaxel
- Arms
- Modified Folfirinox · Active comparator
- Gemcitabine/nab-Paclitaxel · Active comparator
- Enrollment
- 150
- Primary outcomes
- Progression free survival(PFS) in mFFX and GA arms pancreatic ductal adenocarcinoma (PDAC) in a randomized phase II trial.
- Sponsor
- University Health Network, Toronto with Johns Hopkins University, Cold Spring Harbor Laboratory, Ontario Institute for Cancer Research, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Stand Up To Cancer
- Start
- Oct 14, 2020
- Primary completion
- Mar 5, 2025
- Results posted
- No
- Registry record
- NCT04469556 · updated Feb 20, 2026